Debanjana Chatterjee

Debanjana Chatterjee

Auto-generated profile, based on publicly available information

Debanjana Chatterjee

Department of Clinical Immunology and Rheumatology, Hannover Medical School, 30625 Hannover, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2014 in Blood
Verified
Journal Article
Closed access
PDF file
DCDebanjana Chatterjee
Debanjana Chatterjee
DTDejene Milkessa Tufa
Dejene Milkessa Tufa
HBHeike Baehre
Heike Baehre
Ralf HassRalf Hass
Ralf Hass
RSReinhold Ernst Schmidt
Reinhold Ernst Schmidt
RJRoland Jacobs
Roland Jacobs

29 December 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
DCDebanjana Chatterjee
Debanjana Chatterjee
NMNicole Marquardt
Nicole Marquardt
DTDejene Milkessa Tufa
Dejene Milkessa Tufa
THTim Hatlapatka
Tim Hatlapatka
Ralf HassRalf Hass
Ralf Hass
RJRoland Jacobs
Roland Jacobs
Following allogeneic hematopoietic stem cell transplantation (HSCT), interferon (IFN)-gamma levels in the recipient’s body can strongly influence the clinical outcome. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are lucrative as biological tolerance-inducers in HSCT settings. Hence, we studied the molecular mechanism of how UC-MSCs influence natural killer (NK) cell-mediated IFN-gamma production. Allogeneic NK cells were cultured in direct contact with UC-MSCs or cell free supernatants from MSC cultures (MSC conditioned media). We found that soluble factors secreted by UC-MSCs strongly suppressed IL-12/IL-18-induced IFN-gamma production by NK cells by reducing phosphorylation of STAT4, NF-kB as well as T-bet activity. UC-MSCs secreted considerable amounts of Activin-A, which could suppress IFN-gamma production by NK cells. Neutralisation of Activin-A in MSC-conditioned media significantly abrogated their suppressive abilities. Till date, multiple groups have reported that prostaglandin (PG)-E2 produced by MSCs can suppress NK cell functions. Indeed, we found that inhibition of PGE2 production by MSCs could also significantly restore IFN-gamma production. However, the effects of Activin-A and PGE2 were not cumulative. To the best of our knowledge, we are first to report the role of Activin-A in MSC-mediated suppression of IFN-gamma production by NK cells.

1 August 2017 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
SSSarah B. See
Sarah B. See
KCKevin J. Clerkin
Kevin J. Clerkin
PKPeter J. Kennel
Peter J. Kennel
FZFeifan Zhang
Feifan Zhang
MWMatthew P. Weber
Matthew P. Weber
EZEmmanuel Zorn
Emmanuel Zorn

1 March 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DCDebanjana Chatterjee
Debanjana Chatterjee
CMCarolina Moore
Carolina Moore
BGBaoshan Gao
Baoshan Gao
KCKevin J. Clerkin
Kevin J. Clerkin
SSSarah B. See
Sarah B. See
EZEmmanuel Zorn
Emmanuel Zorn

1 January 2013 in Human Gene Therapy
Verified
Journal Article
Closed access
SRShamim H. Rahman
Shamim H. Rahman
SBSylwia Bobis-Wozowicz
Sylwia Bobis-Wozowicz
DCDebanjana Chatterjee
Debanjana Chatterjee
KGKatharina Gellhaus
Katharina Gellhaus
KPKaweh Pars
Kaweh Pars
Toni CathomenToni Cathomen
Toni Cathomen
Parameters that regulate or affect the cell cycle or the DNA repair choice between non-homologous end-joining and homology-directed repair (HDR) are excellent targets to enhance therapeutic gene targeting. Here, we have evaluated the impact of five cell-cycle modulating drugs on targeted genome engineering mediated by DNA double-strand break (DSB)-inducing nucleases, such as zinc-finger nucleases (ZFNs). For a side-by-side comparison, we have established four reporter cell lines by integrating a mutated EGFP gene into either three transformed human cell lines or primary umbilical cord–derived mesenchymal stromal cells (UC-MSCs). After treatment with different cytostatic drugs, cells were transduced with adeno-associated virus (AAV) vectors that encode a nuclease or a repair donor to rescue EGFP expression through DSB-induced HDR. We show that transient cell-cycle arrest increased AAV transduction and AAV-mediated HDR up to six-fold in human cell lines and ten-fold in UC-MSCs, respectively. Targeted gene correction was observed in up to 34% of transduced cells. Both the absolute and the relative gene-targeting frequencies were dependent on the cell type, the cytostatic drug, the vector dose, and the nuclease. Treatment of cells with the cyclin-dependent kinase inhibitor indirubin-3′-monoxime was especially promising as this compound combined high stimulatory effects with minimal cytotoxicity. In conclusion, indirubin-3′-monoxime significantly improved AAV transduction and the efficiency of AAV/ZFN-mediated gene targeting and may thus represent a promising compound to enhance DSB-mediated genome engineering in human stem cells, such as UC-MSCs, which hold great promise for future clinical applications.

29 October 2014 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DTDejene M. Tufa
Dejene M. Tufa
DCDebanjana Chatterjee
Debanjana Chatterjee
HLHui Z. Low
Hui Z. Low
RSReinhold E. Schmidt
Reinhold E. Schmidt
RJRoland Jacobs
Roland Jacobs